Ikarian Capital’s Sonnet BioTherapeutics SONN Stock Holding History

Ikarian Capital’s Portfolio SONN Stock Details SONN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-150,000	Closed	-$687K	–	217
2025 Q3	$687K	Buy	+150,000	New	+$665K	0.07%	134

Other funds holding SONN

FAM

Formidable Asset Management Cincinnati, Ohio $629M AUM 15.56% 1-Year Est. Return

Ikarian Capital's SONN Position: Q4 2025 in Review

Ikarian Capital sold out of Sonnet BioTherapeutics (SONN) in Q4 2025, closing a stake of 150,000 shares — an estimated $687K sold.

Ikarian Capital first reported a position in SONN in Q3 2025 and held it in 1 quarter. The position peaked at $687K in Q3 2025. 1 fund tracked by Wall St. Rank holds SONN as of Q4 2025.

Ikarian Capital reported no remaining Sonnet BioTherapeutics position as of Q4 2025 after selling out during the quarter.
Ikarian Capital sold 150,000 Sonnet BioTherapeutics shares in Q4 2025, an estimated $687K.
Ikarian Capital first reported a position in Sonnet BioTherapeutics in Q3 2025 and held it in 1 quarter.
Ikarian Capital's Sonnet BioTherapeutics position peaked at $687K in Q3 2025.
1 fund tracked by Wall St. Rank held Sonnet BioTherapeutics as of Q4 2025.

Based on Ikarian Capital's 13F filing for Q4 2025, filed 18 Feb 2026.